A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells.
EphA2 is a receptor tyrosine kinase and can be acted as an attractive antigen for glioma vaccines. In addition, LIGHT plays an important role on enhancing T cell proliferation and cytokine production. To improve the CTL mediated immune response against glioma cells, we prepared the novel vaccine containing EphA2(883-891) peptide (TLADFDPRV) and LIGHT plasmid and utilized it to immunize the HLA-A2 transgenic HHD mice. In addition, trimera mice were immunized with the novel vaccine to elicit the antitumor immune response. The results demonstrated that the novel vaccine could induce robust cellular immunity against glioma U251 cells without lysing autologous lymphocytes. Moreover, the novel vaccine could significantly inhibit the tumor growth and prolong the life span of tumor bearing mice. These findings suggested that the novel vaccine containing EphA2 epitope and LIGHT plasmid could induce anti-tumor immunity against U251 cells expressing EphA2, and provided a promising strategy for glioma immunotherapy.
Department of Neurosurgery, Fuzhou General Hospital of Nanjing Command, Fuzhou Fujian, China.
Hongjie
H
Chen
Bangqing
B
Yuan
Zhaocong
Z
Zheng
Zheng
Z
Liu
Shousen
S
Wang
Yong
Y
Liu
D000595:Amino Acid Sequence; D000818:Animals; D019556:COS Cells; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D002522:Chlorocebus aethiops; D058501:Enzyme-Linked Immunospot Assay; D000939:Epitopes / Q000276:immunology; D005910:Glioma / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D015789:HLA-A2 Antigen / Q000032:analysis / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects* / Q000276:immunology; D007114:Immunization; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000138:chemical synthesis / Q000276:immunology / Q000494:pharmacology*; D010957:Plasmids / Q000737:chemistry / Q000276:immunology; D036104:Receptor, EphA2 / Q000737:chemistry / Q000276:immunology*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology
D019496:Cancer Vaccines; D000939:Epitopes; D015789:HLA-A2 Antigen; D009842:Oligopeptides; D007371:Interferon-gamma; D036104:Receptor, EphA2